23
total announcements
AKUMS.NS · 15 min delayed
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts meet on September 2, 2026, at Hyatt, Santacruz East, Mumbai.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in an Investor/Analysts Meet on August 25, 2026, due to medical reasons.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts meet on August 25, 2026, at Trident, BKC, Mumbai.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the transcript of the investors/analysts conference call held on August 10, 2026, for the unaudited financial results of Q1 FY 27.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts meet on August 14, 2026, at Grand Hyatt, India, and will not share any unpublished price sensitive information during the meet.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the link of recording of Investors/Analysts Conference Call held for the un-audited financial results for the quarter ended June 30, 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has published its un-audited financial results for the quarter ended June 30, 2026, as approved by the Board of Directors. The results are available on the company's website and through a Quick Response (QR) Code in newspaper advertisements.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its Initial Public Offer (IPO). The report, issued by CRISIL Ratings Limited, Monitoring Agency, indicates that the company has not deviated from the objects of the issue.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Presentation for Q1 FY27 Investor Meet/Con. Call Updates. The company has registered a healthy revenue growth of over 13% with EBIDTA increasing by more than 30%. The acquisition of Oriflame India's Manufacturing business is expected to expand the company's manufacturing footprint in skincare cosmetics and wellness products.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has reported a 13.9% YoY revenue growth in Q1 FY27, with operating revenue of ₹1,167 crore and PAT of ₹101 crore.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Un-audited Financial Results for the Quarter ended 30th June, 2026'. The Board of Directors has considered and approved the Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended June 30, 2026, along with the Limited Review Reports thereon.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Reports from the Statutory Auditors, Walker Chandiok & Co LLP. The results are available on the company's website.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts conference call for Q1 FY 27 un-audited financial results.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has announced the acquisition of Oriflame India's manufacturing business for INR 56 Crore. The acquisition includes two manufacturing plants and a leased warehouse, marking Akums' entry into the color cosmetics market and expanding its presence in skincare & wellness products.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizer's report of Annual General Meeting held on July 10, 2026, and informed the Exchange regarding voting results. The company has received approval for financial statements, dividend declaration, and director re-appointment, with all resolutions passed with significant majorities.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited held its 22nd Annual General Meeting on July 10, 2026, through video conferencing. The meeting was attended by the Managing Director, Chief Financial Officer, Company Secretary, and representatives of the Statutory Auditors and Secretarial Auditors. The Chairman presented the Financial Highlights for FY 2025-26, including a proposed dividend, and discussed the Company's growth strategy, innovation, and commitment to sustainability and governance.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has received a certificate from MUFG Intime India Private Limited, its Registrar & Share Transfer Agent, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited's wholly-owned subsidiary, Maxcure Nutravedics Limited, has had a penalty of INR 3,59,10,000/- imposed by the Deputy Commissioner of State Tax, Gujarat, set-aside by the First Appellate Authority, Ahmedabad, Gujarat.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has closed its trading window for designated persons from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ending June 30, 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has announced the publication of newspaper advertisements for its 22nd Annual General Meeting (AGM). These advertisements appeared in Business Standard (English and Hindi) on June 19, 2026. The AGM is scheduled to be held on Friday, July 10, 2026, at 11:00 AM (IST) via Video Conferencing or other audio means. This procedural announcement, made in compliance with SEBI regulations, provides shareholders with crucial information for attending and participating in the company's annual governance process.